Expression of USP44 in Hepatocellular Carcinoma and Its Correlation with the Prognosis
10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2021.0513
- VernacularTitle:泛素特异性蛋白酶44在肝细胞癌中的表达及预后价值
- Author:
Sui-jing WANG
1
;
Jie-yi LAI
1
;
Li-hong ZHANG
1
;
Zi-zi LI
2
;
Xin-ke ZHANG
1
;
Jie-wei CHEN
1
Author Information
1. State Key Laboratory of Oncology in South China//Department of Pathology，Sun Yat-Sen University Cancer Center，Guangzhou 510060， China
2. Department of Pathology， the Fifth Affiliated Hospital of Sun Yat-sen University， Zhuhai 519000 ，China
- Publication Type:Journal Article
- Keywords:
ubiquitin specific protease 44;
hepatocellular carcinoma;
immunohistochemistry;
prognosis
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2021;42(5):746-755
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the expression of Ubiquitin specific protease 44（USP44）and its clinical significance in hepatocellular carcinoma（HCC）. MethodsImmunohistochemistry was used to detect the expression of USP44 protein in 161 cases of hepatocellular carcinoma. The correlation between the expression of USP44 protein and clinicopathological parameters，and its prognosis value were analyzed. ResultsImmunohistochemical analysis showed USP44 displayed elevated expression in 98 HCC cases out of 161 cases. Pearson′s chi-square test indicated the expression of USP44 in HCC was significantly correlated with clinical stage（χ2=14.44，P＜0.001） and tumor multiplicity（Unifocal or Multifocal）（χ2 =8.04，P=0.005）. Kaplan-Meier analysis indicated patients with low USP44 expression correlated with poor overall survival（Log-rank χ2=20.77，P＜0.001）.The overall mean survival time was 59.6 months in low USP44 expression patients and 185.0 months in high USP44 expression patients. The Cox proportional hazard model analysis showed USP44 was an independent prognostic risk factor for HCC patients. ConclusionUSP44 is an independent prognostic risk factor for HCC patients， and the expression of USP44 protein could be used to screen patients with good prognosis for HCC. Our study may provide evidence for USP44 as a potential therapeutic target for HCC patients.
